Brokers Issue Forecasts for Augmedix, Inc.’s Q1 2024 Earnings (NASDAQ:AUGX)
Augmedix, Inc. (NASDAQ:AUGX – Free Report) – B. Riley issued their Q1 2024 EPS estimates for Augmedix in a report issued on Tuesday, April 2nd. B. Riley analyst Y. Zhi expects that the company will post earnings of ($0.12) per share for the quarter. B. Riley currently has a “Buy” rating and a $5.50 price target on the stock. B. Riley also issued estimates for Augmedix’s Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.13) EPS and FY2024 earnings at ($0.51) EPS.
A number of other research analysts also recently issued reports on the stock. Maxim Group reduced their price objective on shares of Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th. Evercore ISI reduced their price objective on shares of Augmedix from $6.50 to $4.50 and set an “in-line” rating on the stock in a research report on Tuesday, March 19th.
Read Our Latest Stock Analysis on AUGX
Augmedix Stock Down 3.6 %
Shares of Augmedix stock opened at $4.03 on Friday. The company has a current ratio of 2.41, a quick ratio of 2.41 and a debt-to-equity ratio of 0.66. The company’s fifty day simple moving average is $4.19 and its two-hundred day simple moving average is $4.86. The company has a market cap of $196.42 million, a P/E ratio of -8.96 and a beta of -0.16. Augmedix has a 12-month low of $1.50 and a 12-month high of $6.25.
Insider Activity
In related news, insider Ian Shakil sold 31,994 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $4.06, for a total value of $129,895.64. Following the transaction, the insider now owns 187,666 shares in the company, valued at approximately $761,923.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 136,878 shares of company stock worth $549,173. Corporate insiders own 10.97% of the company’s stock.
Hedge Funds Weigh In On Augmedix
A number of hedge funds have recently bought and sold shares of AUGX. Perkins Capital Management Inc. raised its position in Augmedix by 5.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,464,568 shares of the company’s stock worth $8,568,000 after buying an additional 73,475 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Augmedix by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 1,122,890 shares of the company’s stock valued at $6,569,000 after purchasing an additional 84,294 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Augmedix by 170.1% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company’s stock valued at $5,943,000 after purchasing an additional 639,732 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Augmedix by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock valued at $5,213,000 after purchasing an additional 663,778 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Augmedix during the 3rd quarter valued at about $2,237,000. Institutional investors own 87.11% of the company’s stock.
About Augmedix
Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient’s health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.
Further Reading
Receive News & Ratings for Augmedix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Augmedix and related companies with MarketBeat.com’s FREE daily email newsletter.
